Drug Discovery & Development

Home » Drug Discovery & Development

Invenra and Exelixis Partnership to Provide New Anticancer Therapies

Biotech start-up Invenra recently announced a partnership collaboration with Exelixis to develop multispecific antibodies as cancer therapies. Their partnership agreement allows Exelixis to expand its current small molecule pipeline to create a biologics pipeline able to provide new anti-ancer therapies, says GlobalData, a leading data and analytics company. The partnership combines the biological insight, clinical [...]

72% of Life Science Professionals Believe Their Industry is Behind in the Development of AI

A survey of 229 life science professionals from The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has found the majority (72%) believe their sector is lagging behind other industries in its development of AI. To accelerate the successful use of AI, The Pistoia [...]

Aptar Pharma and Propeller Health Partner to Develop Digital Medicine Platform Across Therapeutic Areas

Aptar Pharma, a leading provider of innovative drug delivery systems, and Propeller Health, a leading digital therapeutics company, have announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The digital medicine platform, spanning inhaled, injectable, nasal and dermal medicine delivery forms, will combine software and experiences with [...]

If Approved, Risankizumab Would Further Strengthen AbbVie’s Position in Psoriasis Market

If European approval is granted for AbbVie’s risankizumab for moderate-to-severe plaque psoriasis, the company could further strengthen its position in the psoriasis market, according to GlobalData, a leading data and analytics company. In 2017, AbbVie reported that Humira (adalimumab), an anti-tumour necrosis factor (TNF) biologic indicated for multiple immunological disorders including psoriasis, generated global sales [...]

Alcami Announces Industry Leading Analytical Testing Turnaround Time

Alcami Corporation, a leading provider of fully integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, announces the advancement of the drug development process with the company's new, dramatically reduced analytical testing turnaround times. Alcami continues to set the industry standard with its analytical testing offering, and through operational excellence, streamlined processes, and technical [...]

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics Limited (aTen), a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, have entered into a strategic collaboration. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen. [...]

Enamine and BioSolveIT Launch the World’s Largest Searchable Chemical Space for Novel Compound Sourcing

Enamine Ltd, a leading chemical research organisation and producer of the world’s largest collections of novel building blocks (150,000) and screening compound libraries (2,400,000), and BioSolveIT GmbH, premium provider of medicinal chemistry software, have announced the launch of the REAL Space Navigator. Jointly developed, the new software tool capitalises on Enamine’s REAL (readily accessible) virtual [...]

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

Helsinn International Services, a Monaco-based affiliate of the Swiss Pharmaceutical Group focused on building quality cancer care products, and the Scientific Centre of Monaco (CSM), have signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer: clear cell renal cell carcinoma (ccRCC). ccRCC [...]

Follicum Identifies Receptors in Insulin-Producing Cells for Potential New Class of Diabetes Drugs

Follicum AB has successfully mapped the receptors in insulin-producing cells that bind the company’s peptides. The new knowledge represents an important milestone in the continued development of the company's diabetes project and opens the possibility of the identified receptors becoming potential drug targets for stimulating insulin secretion and reduction of diabetic complications. Investigation of mechanism [...]

Avacta and Oncosec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers

Avacta Group, the developer of Affimer biotherapeutics and reagents, and OncoSec Medical Incorporated (OncoSec), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse. The research programme will evaluate the benefits of delivering Affimer protein genes [...]